Monoclonal antibodies targeting immune inhibitory receptors including anti‐programmed death receptor‐1 (anti‐PD‐1) and anti‐cytotoxic T‐lymphocyte‐associated antigen‐4 (anti‐CTLA‐4) can reverse T‐cell dysfunction and thus enhance tumor‐specific T‐lymphocyte activity.1 Here, CTLA4 is linked to neoplasm.